C-reactive protein is a strong predictor of mortality in hemodialysis patients

Renal Failure

Volumn 28, Issue 5, 2006, Pages 427-433

  Rački, Sanjin ^a   Zaputović, Luka ^a   Mavrić, Žarko ^a   Vujičić, Božidar ^b   Dvornik, Štefica ^a  

^a KBC RIJEKA   (Croatia)

^b Health Centre Umag   (Croatia)

Author keywords

C reactive protein; Chronic inflammation; Hemodialysis; Kidney failure chronic; Mortality

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL ANALYSIS; SURVIVAL;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 33745903398     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220600683581     Document Type: Article

References (32)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis. 1998; 32(Suppl 5):S112-119.
2. Cheung AK, Sarnak MJ, Guofen Y et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58:353-362.
3. Racki S, Zaputovic L, Vujicic B, Mavric Z, Grzetic M, Ravlic-Gulan J. Cardiovascular risk factors and diseases strongly predict hemodialyis treatment outcome in maintenance hemodialysis patients. Croat Med J. 2005;46(6):936-941.
4. Stenvinkel P. Inflammation in end-stage renal disease - a fire that burns within. In Ronco C, Brendolan A, Levin NW, eds. Cardiovascular Disorders in Hemodialysis. Basel: Karger; 2005:185-199.
5. Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol. 2002;13:1307-1320.
6. Eknoyan G, Beck GJ, Cheung AK, et al., for the Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010-2019.
7. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524-1538.
8. Tracy RP. Inflammation in cardiovascular disease. Circulation. 1998;97:2000-2002.
9. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
10. Yao Q, Lindholm B, Stenvinkel P. Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodialysis Int. 2004;8:118-129.
11. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practise. A statement for healthcare professionals from the Centres for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
12. Stenvinkel P, Alvestrand P. Inflammation in end-stage renal disease: Sources, consequences and therapy. Semin Dial. 2002;15:329-337.
13. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNFα: central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int. 2005;67:1216-1233.
14. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000;35:469-476.
15. Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant. 1999;14:1956-1960.
16. Nascimento MN, Pecoits-Filho R, Qureshi AR, et al. The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. Nephrol Dial Transplant. 2004;19:2803-2809.
17. Stenvinkel P, Heimbürger O, Paultre F, et al. Strong association between malnutrition and atherosclerosis in chronic renal patients. Kidney Int. 1999;55:1899-1911.
18. Baudner S, Dali F. Standardization of the measurement of 14 proteins in human serum based on the new IFCC/BCR/CAP international reference material CRM 470. J Lab Med. 1996;20:145-152.
19. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997;43:52-58.
20. Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta. 1971;31:87-96.
21. Painter PC, Cope JY, Smith JE. Reference information for the clinical laboratory. In Burtis CA, Ash wood ER, eds. Tietz Textbook of Clinical Chemistry. Philadelphia: WB Saunders Company; 1999:1800.
22. Depner T, Beck B, Daugirdas J, Kusek J, Eknoyan G. Lessons from the hemodialysis (HEMO) study: an improved measure of the actual hemodialysis dose. Am J Kidney Dis. 1999;33:142-149.
23. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1615-1617.
24. Menon V, Greene T, Wang X, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int. 2005;68:766-772.
25. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int. 1998;54:627-636.
26. Chauveau P, Level C, Lasseur C, et al. C-reactive protein and procalcitonin as markers of mortality in hemodialysis patients: a two-year prospective study. J Ren Nutr. 2003;13:137-143.
27. Tellingen A, Grooteman MPC, Schoorl M, et al. Intercurrent clinical events are predictive of plasma C-reactive protein levels in hemodialysis patients. Kidney Int. 2002;62:632-638.
28. Tsirpanlis G, Bagos P, Ioannou D, et al. The variability and accurate assessment of microinflammation in haemodialysis patients. Nephrol Dial Transplant. 2004;19:150-157.
29. Ockene IR, Matthews CE, Rifai N, et al. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem. 2001;47:444-450.
30. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648-658.
31. Korevaar JC, Manen JG, Dekker FW, Waart DR, Boeschoten EW, Krediet RY, for the NECOSAD study group. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol. 2004;15:2916-2922.
32. National Kidney Foundation. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI. National Kidney Foundation. Am J Kidney Dis. 2000;35(6, Suppl. 2):1-140.